Humanetics is a privately held, clinical stage pharmaceutical company located in the Minneapolis metropolitan area.  Our lead candidate, BIO 300 is being developed for multiple clinical uses with a primary focus on improving treatment of solid tumor cancers. BIO 300 is being developed as an agent to both sensitize tumor cells to enhance radiation treatment efficacy and to protect normal tissues from harm. Thus, reducing common treatment related side effects such as radiation induced pneumonitis, erectile dysfunction, mucositis and xerostomia.  BIO 300 is also under development for inflammatory lung diseases with an immediate focus on mitigation of pulmonary injury due to COVID-19.  A recent contract from NIAID will fund a phase 2 study on BIO 300 in recovering COVID patients in an effort to stem progressive long-term lung complications, such as fibrosis.

BIO 300 was licensed from the US Department of Defense, where it was originally developed to prevent injuries associated with ionizing radiation.  This program is still underway with a focus on prevention of acute radiation syndrome as well as lung injury.
 
For more information about Humanetics, please visit our corporate website at www.humaneticscorp.com.

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Humanetics Corporation

Humanetics Corporation's headquarters in Minneapolis, United States

Ronald J. Zenk

Colin Chinn

Michael Kaytor

This department focuses on overseeing and guiding the organization through strategic direction and decision-making.

Board Governance

This department oversees the intersection of medical expertise and scientific research, driving innovation and compliance across health initiatives.

Humanetics Corporation

Org chart

Teams

Board Governance

Medical and Scientific Affairs

Offices

Humanetics Corporation

Org chart

Teams

Board Governance

Medical and Scientific Affairs

Offices

Related companies